Fetal cells enter the maternal circulation during pregnancy and can persist in the maternal blood or tissues for decades, creating a physiologic microchimerism. Because papillary thyroid cancer (PTC) is more frequent in women, the role of persisting fetal male cells in this tumor has been investigated. Tumor tissue specimens were obtained from 63 women with PTC who had a male pregnancy before the diagnosis. Male cells, identified by PCR amplification of a male-specific gene, the sex-determining region Y, was detected in 47.5% of women. By fluorescence in situ hybridization (FISH) analyses, the total number of microchimeric cells was significantly higher in neoplastic tissue than in controlateral normal sections. By combined FISH and immunohistochemistry (immuno-FISH), male cells expressing thyroglobulin were found in tumor and normal tissues, whereas male microchimeric cells stained with the CD45 antigen were detected only in tumor sections. Microchimeric cells negative for either marker were detected both in tumor and normal tissues. Moreover, both CD45 + and Tg + fetal cells did not express MHC II antigens. In conclusion, fetal microchimerism has been documented in a high proportion of women with PTC. The immuno-FISH studies indicate that CD45
Introduction
Fetal cell microchimerism (FCM) is defined as the persistence of fetal cells in maternal organs and circulation without any apparent graft-versus-host reaction or graft rejection (1, 2) . It can take place during pregnancy, when a bidirectional trafficking of cells has been observed starting from the 4th to 6th week of gestation (3) . A wide variety of fetal cells have been detected in maternal blood, including trophoblasts, hematopoietic stem cells and CD34 + CD38 + cells, mesenchymal stem cells, nucleated erythroblasts, T and B lymphocytes, monocytes, and natural killer (NK) cells (4) . FCM have been hypothesized to be involved in chronic inflammatory responses leading to tissue damage (''bad microchimerism'') or to participate in the repair of damaged tissue and in the resistance to infections (''good microchimerism''), although it cannot be excluded that it might not have any biological significance (''neutral microchimerism''; ref. 5) . The commonest approach to detect foreign cells has been the assay of male-specific gene markers in females with a previous male pregnancy, by PCR amplification of the sex-determining region Y (SRY; refs. 6, 7) or by Fluorescence in situ hybridization (FISH) with labeling of X-and Y-chromosomes (8) . FCM was first documented in autoimmune diseases, such as systemic sclerosis, primary biliary cirrhosis, Sjögren's syndrome or erythematosus systemic lupus, type 1 diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, and has been hypothesized by several authors to be implicated in the pathogenesis (6, 7, (9) (10) (11) (12) (13) (14) (15) . Differently, the role of microchimeric cells in nonautoimmune disorders, such as hepatitis C, thyroid adenoma and multinodular goitre, and cervical and breast cancer is still controversial (8, (16) (17) (18) . In this context, it has been speculated that the presence of these foreign cells in tissues might be the consequence rather than the cause of disease, and that they might provide a source of progenitor cells, participating in maternal tissue repair processes (17, 19) , as suggested by the finding of male cells forming a thyroid follicle in a woman with multinodular goiter (8) . Finally, it has been recently suggested that FCM might contribute to reduce the risk to develop breast cancer (18) .
In the present study, the role of microchimerism in papillary thyroid cancer (PTC) was investigated. A possible involvement of this phenomenon might be indeed hypothesized because this tumor is two to four times more prevalent in females. Molecular and cytogenetic analyses were performed to recognize fetal male cells in neoplastic and normal tissues from 63 women with PTC. Furthermore, to determine the phenotype of male cells, combined FISH and immunohistochemistry (immuno-FISH) studies were performed using common leukocyte antigen CD45 as a leukocyte marker, and thyroglobulin as a follicular thyroid cells marker. Finally, to obtain more insights into the understanding of the role of microchimeric cells, MHC II expression has been evaluated.
Materials and Methods
Thyroid tissue samples. Tumor tissue fresh-frozen specimens were obtained from 63 women who underwent thyroidectomy for PTC. They were divided into 2 groups: group 1 (n = 40) included women who had at least 1 male pregnancy before the diagnosis of PTC and group 2 (n = 23) that included women who had only female offspring or were nulliparous. The latter group was used as negative control, whereas DNAs obtained from the tumor thyroid tissue or blood samples of 10 men were used as positive controls. No patients or negative controls had history of other potential sources of microchimerism (i.e., blood transfusion, organ transplantation, or twin sibling). Moreover, none of the women from the negative control group had history of abortion.
DNA extraction from frozen tissue and from whole blood. Tissue DNA was extracted, by standard methods, from frozen thyroid tumors corresponding to the 63 women enrolled. In 20 of 40 patients of group 1, tissue DNA was also obtained from frozen normal thyroid samples controlateral to the tumor. As positive control, tissue DNA was extracted from frozen normal thyroid tissues corresponding to six men. Paraffinembedded tissues have not been used to avoid differences in DNA yield and quality and thus in PCR sensitivity.
Genomic DNA was extracted, by standard methods, from whole blood of four men, who were used as positive controls. Female technicians handled all tissue samples.
PCR for Y-chromosome SRY sequence. For the detection of the human Y-chromosome, specific primers for the SRY locus corresponding to areas upstream of the SRY-coding region and adequate PCR conditions were used (6, 7) . All PCR analysis contained two negative and two positive controls and were prepared taking special caution to avoid external contamination. In particular, all samples were handled by females, positive micropipettes were used, and DNA extraction, PCR preparation, and PCR analysis were conducted in separate rooms. Moreover, all results have been confirmed twice.
FISH. FISH analyses were performed (patients #1, 3, 5, and 7) on 5-Am thick paraffin-embedded tissue sections as previously described (20, 21) . After revision of all the slides by the pathologist (S.R.), a total of two to six sections from each patient were scanned. The DNA probes used were specific for the a-satellite regions of the X (BAC probe pDMX1, locus DXZ1) and Y (band region Yp11.1-q11.1, locus DYZ3) chromosomes. The X probe was labeled with digoxigenin and detected using FITC-conjugated antibody antidigoxigenin (green signal; Roche), whereas the Y was labeled with a SpectrumOrange fluorochrome (Vysis) and detected as red signal.
Immuno-FISH. To immunophenotype fetal male cells, a FISH and immunohistochemistry combined method was used (22, 23) . Tissues sections were first subjected to two-color immunohistochemistry with anti-CD45 (mouse monoclonal antibody; Dako) and anti-Tg (polyclonal rabbit antibody, Biogenex Laboratories, Inc.) antibodies. Secondary antibodies and peroxidase and phosphatase-alkaline enzymes conjugated to polymers (Picture Plus Double Staining kit; Zymed Laboratories, Inc.; Invitrogen) were used and developed with substrates 3,3 ¶-diaminobenzidine (DAB; brown precipitate) and Fast Red (visible as red fluorescence or red precipitate). Subsequently, the same sections were probed for X-and Y-chromosomes and counterstained with 4 ¶,6-diamidino-2-phenylindole.
To study MHC class II expression in CD45 + and Tg + fetal cells, male cells were identified by FISH analysis and electronic coordinates were taken. Anti-CD45 antibody was used together with a secondary antibody NOTE: BRaf V600E mutation and RET rearrangements (ret/PTC1, 2, and 3) have been analyzed starting from tissue DNA and RNA, as previously described (26, 27) . In all these cases, male cells were detected by PCR in the neoplastic tissue. The results obtained in the normal controlateral thyroid tissue, whenever available, are also reported. * Associated nontoxic goiter. cClassic variant. bBRaf mutation.
x ret/PTC rearrangement. k Associated resistance to thyroid hormones. { no BRaf or ret/PTC mutations; P, persistence of disease; R, remission of disease; n.a., not available. ** Follicular variant. ccAssociated lymphocytic thyroiditis at histology.
antimouse phosphatase-alkaline conjugated (mouse IgG antibody preadsorbed; GeneTex) and developed with Fast Red, whereas for Tg staining, the same method described above was used. In both cases, antibodies were detached and samples stained with MHC II antibody (MHC DR+DP+DQ; monoclonal mouse; GeneTex). Secondary antibody and peroxidase enzyme conjugated to polymer were used and developed with DAB substrate.
Scoring and statistical analyses. Sections were blindly scanned by three separate experts (V.C., M.P.R., and P.F.) for the presence of male cells. Sections were considered only if the loss of cells from the section of tissue during the hybridization procedure was minimal and if >70% of the nuclei had at least one X (green) and one Y (red) signal within a clearly defined nucleus. 
Results
Identification of male DNA in tumor and normal thyroid tissues. The presence of male DNA was detected in the tumor tissue of 19 of 40 women with PTC who had at least one male pregnancy before the diagnosis of tumor (group 1), whereas it was absent in tumor thyroid tissue from 23 patients with only female offspring or nulliparous (group 2; Supplementary data). In 20 of 40 women of group 1, the normal tissue controlateral to the PTC was also analyzed and male DNA was found only in 5 cases, who were positive also at the tumor level (Table 1) . Interestingly, in patients positive for the presence of FCM, the delivery of male occurred up to 46 years before thyroidectomy. It is worth to note that only 2 of 19 tumors positive for FCM had an associated autoimmune thyroiditis at histology. No significant differences in the age at diagnosis, in the pathologic stage (tumor-node-metastasis classification, American Joint Committee on Cancer 6th edition; ref. 24) , in the outcome, and in the genetic alteration (BRaf V600E mutation or ret/PTC rearrangements) were found between patients positive or negative for the presence of microchimerism.
Identification of male microchimeric cells in tumor and normal thyroid tissues. To further characterize the data obtained by PCR, a FISH was performed on paraffin-embedded neoplastic and normal tissues from women who were positive for the presence of SRY sequence. Due to the high number of cells to examine in each section (up to 2,000,000 per sample; Table 2 ), 4 exemplificative cases were selected based only on the availability of sufficient quantity of paraffin-embedded tissues. The presence of one chromosome Y (red signal) and one X chromosome (green signal) in the nuclei identified male cells. Microchimeric cells were detected in all cases, as single cells or in cluster. The number of microchimeric cells ranged 1.8 to 7.8 per section in tumors and 0 to 1.5 per section in normal samples ( Table 2 ). The number of microchimeric male cells per million total cells examined was significantly higher in neoplastic thyroid tissue than in normal sections (P = 0.02, by Mann-Whitney rank sum test).
Phenotype of male microchimeric cells in neoplastic and normal tissues. To characterize the phenotype of male cells in PTCs and normal controlateral tissues, immunohistochemistry with antibodies against the hematopoietic marker CD45 and against the thyrocyte marker Tg and FISH for X-and Ychromosome were simultaneously performed (Figs. 1 and 2 ). Male cells expressing Tg were found both in tumor and normal thyroid tissues (66% versus 49%), whereas male microchimeric cells stained with CD45 were detected in a lower number and only in neoplastic tissue sections (13% versus 0%). Microchimeric cells negative for either marker were detected both in tumor and normal tissues, but they were significantly more frequent in normal tissue (51% versus 21%; Table 3 ). The immunophenotypic characterization resulted significantly different between tumoral and normal tissue (P < 0.0001, m 2 test). No cells positive for both markers were found. Interestingly, in some sections, Tg + male cells were interposed between maternal follicular cells forming a thyroid follicle (Fig. 1) . Either CD45 + or Tg + fetal cells did not express MHC II antigens (Fig. 3) . On the contrary, a MHC II staining was observed at the plasma membrane level in female leukocitic cells, and at the cytoplasmatic and membrane level in female thyrocytes (Fig. 3) .
Discussion
The present study shows the presence of FCM, resulting from feto-maternal cell trafficking, in PTC. Male SRY sequences were identified in the tumor tissue of 19 of 40 (47.5%) women with PTC who had at least 1 male pregnancy and in normal controlateral thyroid tissue, whereas it was always absent in tumor tissue from patients with only female offspring or nulliparous. Because FCM has been shown in 40% to 50% of Hashimoto's and Graves' tissues (6, 15) , it is worth to note that in the present series, only 2 of 19 PTC positive for FCM were associated with thyroiditis. At variance, the previously reported thyroid cancer cases with FCM were all associated with thyroiditis (8), which might be a possible confounding element especially because male cells were not immunophenotyped.
The number of microchimeric cells has been found to be independent on the number of male pregnancies and on the interval between pregnancy and disease, confirming that fetal cells are present in the maternal blood for decades after delivery (1, 2). + (square ) is surrounded by CD45 + female cells. B, the same male cell visualized by light microscopy is negative for MHC II expression. Differently, MHC II is positive (dark staining on cell membrane; magnification, Â100) in several surrounding female cells (arrows ). C, papillary thyroid tumor section at fluorescence microscopy. A male cell, previously characterized as Tg + and forming part of a papilla (square ) is surrounded by Tg + female cells. D, the same male cell visualized by light microscopy is negative for MHC II expression. In contrast, a weak MHC II staining was found (dark staining on thyrocytes membrane and cytoplasm; magnification, Â100) in several surrounding cells (arrows ).
FISH analyses confirmed and extended PCR data, allowing to quantify the number of fetal cells and demonstrating that they were significantly more represented in tumors than in normal tissue controlateral to PTC, likely excluding the possible role of male cells as innocent bystanders. These data are in accordance with previous data on cervical cancer showing that fetal cells positive for CD45 and for cytokeratin were significantly more abundant in the neoplastic tissue with respect to the adjacent normal tissue, suggesting a role in the repairing process (17) . In the present study, male cells stained with the leukocyte marker CD45 were found at a low frequency (13% of microchimeric cells) and only in tumor tissue sections. Differently, microchimeric cells expressing Tg were detected both in tumor and normal thyroid tissues (66% and 49%, respectively). Interestingly, both CD45 and Tg-positive male cells were found to be negative for MHC II expression. On the contrary, several female cells either CD45 + or Tg + expressed MHC II antigen, consistent with a role as antigenpresenting cells. Indeed, tumoral follicular cells, but not normal thyroid cells, have been shown to harbor the aberrant expression of MHC II antigen, which is believed to be triggered by oncogenes, such as ret/PTC, and to have an immunomodulatory function (25) . Thus, the lack of MHC II expression in Tg + male cells argues against a transformed phenotype and a role as antigen-presenting cells, supporting instead a possible function in the replacement of damaged cells and repair of the thyroid tissue. A role as antigenpresenting cells can be also excluded for CD45 + male cells, which were negative for MCH II expression, suggesting that they could be referred as macrophage or NK cells, likely committed to destroy tumor cells. Male cells negative for the differentiation markers CD45 and Tg were found both in neoplastic and normal tissues (21% and 51%, respectively). As hypothesized for other diseases (22) , these ''negative'' microchimeric cells could be thyrocytes precursors, fibroblast, or stem-like cells migrated to the thyroid and able to differentiate in hematopoietic or epithelial cells. This is in agreement with the idea that during pregnancy, women could acquire pregnancy-associated progenitor cells with the capacity for multilineage differentiation in diseased or injured maternal tissue (2, 19, 23) . Nevertheless, it should be considered that these cells could not be involved in host tissue repair, but they could have a role in carcinogenesis, for example, inducing an immune system alteration or making the thyroid tissue more susceptible to detrimental genetic or environmental factors. This is the first report demonstrating FCM in normal thyroid tissue. Indeed, normal thyroids have been previously found to be negative for FCM (6, 8) . This discrepancy could be due to the different origin of normal samples, from the thyroid tissue controlateral to a neoplastic lesion in the present, and from autoptic normal glands in the other studies. This finding further support the idea that, in the presence of a neoplastic process, microchimeric cells could migrate to the thyroid and participate in the repair process.
Nonetheless, FCM was not detected in tumor tissue from 21 of 40 (52.5%) women affected with PTC who had 1 male pregnancy, consistently with previous data (8) . This could be the consequence of the incomplete analysis of surgical specimens or of the removal of fetal cells by the maternal immune system. It is also worth of mention that, at least in some of these patients, female fetal cells deriving from another pregnancy could have migrated to the maternal thyroid gland.
In conclusion, the present study shows the presence of FCM in a high proportion of women with PTC. 
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